Download Files:
Products Details
Product Description
– Cangrelor (AR-C69931MX), an adenosine triphosphate analogue, is an intravenous, reversible and selective platelet P2Y12 antagonist, with prompt and potent antiplatelet effects. Cangrelor directly blocks adenosine diphosphate (ADP)-induced activation and aggregation of platelets. Cangrelor is also a nonspecific GPR17 antagonist[1][2].
Web ID
– HY-19638
Shipping
– Room temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C17H25Cl2F3N5O12P3S2
References
– [1]Bhattad VB, , et al. Intravenous cangrelor as a peri-procedural bridge with applied uses in ischemic events. Ann Transl Med. 2019;7(17):408.|[2]Zhan T, Wei T, et al. Cangrelor alleviates bleomycin-induced pulmonary fibrosis by inhibiting platelet activation in mice. Mol Immunol. 2020;120:83-92.|[3]BekÅ‘ K, et al. Contribution of platelet P2Y12 receptors to chronic Complete Freund’s adjuvant-induced inflammatory pain. J Thromb Haemost. 2017;15(6):1223-1235.
CAS Number
– 163706-06-7
Molecular Weight
– 776.36
SMILES
– CSCCNC1=C2C(N([C@H]3[C@H](O)[C@H](O)[C@@H](COP(OP(C(Cl)(Cl)P(O)(O)=O)(O)=O)(O)=O)O3)C=N2)=NC(SCCC(F)(F)F)=N1
Clinical Information
– Launched
Research Area
– Inflammation/Immunology; Cardiovascular Disease
Solubility
– 10 mM in DMSO
Target
– P2Y Receptor
Isoform
– P2Y12 Receptor
Pathway
– GPCR/G Protein
Product type
– Reference compound
Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.
